Histone deacetylase inhibitors in cancer: What have we learned?

Abstract

The authors outline the current stage in the development of histone deacetylase inhibitors in solid tumors. Despite single-agent benefit in a small number of hematologic malignancies, evidence in solid organ cancers suggests that outcomes will be more promising with combination therapy and should be the focus of future studies.